Page 2 - Cellular Oncogenesis Program News Today

Using advanced computing technology scientists at the Wistar Institute (Philadelphia) have been able to provide evidence of novel, reliable biomarkers that better predict therapy response of patients undergoing immune checkpoint inhibitor (ICI) treatment. Click to read more...

Researchers have identified key markers to help physicians predict whether or not a patient may respond positively to ...

Immune checkpoint inhibitor (ICI) therapy is a type of treatment for melanoma, the deadliest form of skin cancer, which blocks proteins on tumor or immune cells that prevent the immune system from killing cancer cells.

A Ludwig Cancer Research study has identified a potential vulnerability in neuroblastoma tumors that might be exploited to improve treatment of the aggressive childhood cancer, which accounts for roughly 15% of all deaths from pediatric malignancies.

FEBRUARY 7, 2021, NEW YORK – A Ludwig Cancer Research study has identified a potential vulnerability in neuroblastoma tumors that might be exploited

Indian American-led research from Penn Medicine and The Wistar Institute has been awarded a prestigious $11.7 million Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute.

 E-Mail IMAGE: Wistar scientists characterized an inhibitor that targets acetate metabolism in cancer cells. This molecule caused tumor growth inhibition and regression in preclinical studies, demonstrating the promise of this approach as... view more  Credit: The Wistar Institute PHILADELPHIA -- (Jan. 7, 2021) -- Scientists at The Wistar Institute characterized an inhibitor that targets acetate metabolism in cancer cells. Cancer cells use acetate metabolism to support tumor growth in...